Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. KURA
stocks logo

KURA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
81.55M
+51.34%
-0.109
-50.5%
89.86M
+536.92%
-0.875
+32.58%
--
--
-0.902
+20.33%
Estimates Revision
The market is revising Downward the revenue expectations for Kura Oncology, Inc. (KURA) for FY2025, with the revenue forecasts being adjusted by -20.66% over the past three months. During the same period, the stock price has changed by 45.74%.
Revenue Estimates for FY2025
Revise Downward
down Image
-20.66%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+4.23%
In Past 3 Month
Stock Price
Go Up
up Image
+45.74%
In Past 3 Month
Wall Street analysts forecast KURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KURA is 26.88 USD with a low forecast of 11.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Analyst Rating
Wall Street analysts forecast KURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KURA is 26.88 USD with a low forecast of 11.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
2 Hold
0 Sell
Strong Buy
Current: 11.980
sliders
Low
11.00
Averages
26.88
High
40.00
Current: 11.980
sliders
Low
11.00
Averages
26.88
High
40.00
Barclays
Etzer Darout
Overweight
maintain
$11 -> $28
2025-11-24
Reason
Barclays
Etzer Darout
Price Target
$11 -> $28
2025-11-24
maintain
Overweight
Reason
Barclays analyst Etzer Darout raised the firm's price target on Kura Oncology to $28 from $11 and keeps an Overweight rating on the shares. The firm cites the ziftomenib approval for the target increase.
UBS
David Dai
Buy
maintain
$14 -> $16
2025-11-14
Reason
UBS
David Dai
Price Target
$14 -> $16
2025-11-14
maintain
Buy
Reason
UBS analyst David Dai raised the firm's price target on Kura Oncology to $16 from $14 and keeps a Buy rating on the shares.
Wedbush
Outperform
maintain
$36 -> $38
2025-11-14
Reason
Wedbush
Price Target
$36 -> $38
2025-11-14
maintain
Outperform
Reason
Wedbush raised the firm's price target on Kura Oncology to $38 from $36 and keeps an Outperform rating on the shares. The firm notes Ziftomenib at 600 mg QD dosing was approved in r/r NPM1m AML, ahead of the PDUFA date of November 30th. The approval was based on the KOMET-001 study.
BofA
Jason Zemansky
Buy
maintain
$29 -> $30
2025-11-14
Reason
BofA
Jason Zemansky
Price Target
$29 -> $30
2025-11-14
maintain
Buy
Reason
BofA analyst Jason Zemansky raised the firm's price target on Kura Oncology to $30 from $29 and keeps a Buy rating on the shares. The FDA approval of Kura's ziftomenib as "Komzifti" is "a watershed moment for the company," the analyst tells investors. Following the update, the firm increased odds of success for Komzifti approval to 100% while also adjusting sales to reflect about one month for Komzifti to roll out, driving its revised target.
Guggenheim
Neutral
initiated
2025-09-04
Reason
Guggenheim
Price Target
2025-09-04
initiated
Neutral
Reason
Guggenheim initiated coverage of Kura Oncology (KURA) with a Neutral rating and no price target. The firm expects a near-term relapsed/refractory nucleophosmin 1-mutated acute myeloid leukemia launch for the company buy says it will be difficult to drive value with Syndax (SNDX_ already on market for this smaller patient population.
Guggenheim
Brad Canino
Neutral
initiated
2025-09-03
Reason
Guggenheim
Brad Canino
Price Target
2025-09-03
initiated
Neutral
Reason
Guggenheim analyst Brad Canino initiated coverage of Kura Oncology with a Neutral rating.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Kura Oncology Inc (KURA.O) is -4.31, compared to its 5-year average forward P/E of -6.84. For a more detailed relative valuation and DCF analysis to assess Kura Oncology Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-6.84
Current PE
-4.31
Overvalued PE
-3.41
Undervalued PE
-10.26

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-3.48
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
-0.06
Undervalued EV/EBITDA
-6.89

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
1.06
Current PS
0.00
Overvalued PS
3.66
Undervalued PS
-1.54
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

KURA News & Events

Events Timeline

(ET)
2025-12-02
08:31:00
Kura Oncology Completes First U.S. Sale of KOMZIFTI, Triggers $135 Million Payment
select
2025-11-13 (ET)
2025-11-13
10:54:14
Kura Oncology and Kyowa Kirin Receive FDA Approval for KOMZIFTI in Treating AML
select
2025-11-13
10:12:58
FDA Grants Approval for Kura's Komzifti in Treating AML
select
link
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
9.0
02:13 AMNewsfilter
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
  • Clinical Progress: GT Biopharma has successfully completed the safety review for its GTB-3650 Phase 1 trial, with all six patients treated across the cohorts showing no safety or tolerability issues, indicating strong tolerability of the therapy for relapsed blood cancers.
  • Dose Advancement: The company is now advancing to Cohort 4, where patients will receive a dose of 10μg/kg/day, which is believed to be closer to the clinical efficacy threshold, potentially enhancing treatment outcomes and driving further clinical trial progress.
  • Patient Recruitment: GT Biopharma is actively screening patients for Cohort 4 and anticipates initiating dosing in the coming weeks, which will provide critical clinical data updates in the first quarter of 2026, further boosting investor confidence.
  • Technology Platform: GTB-3650 employs the company's proprietary TriKE platform technology, aiming to target cancer cells by stimulating patients' natural killer cells, demonstrating potential in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
[object Object]
Preview
9.0
01:42 AMPRnewswire
GT Biopharma Completes Safety Review for GTB-3650 Phase 1 Trial
  • Clinical Progress: GT Biopharma has successfully completed the safety review for its GTB-3650 Phase 1 trial, with all six participants showing no safety or tolerability issues at progressively higher doses, indicating the therapy's potential in treating relapsed blood cancers.
  • Dose Advancement: The company has moved into Cohort 4, where patients will receive a dose of 10μg/kg/day, which is expected to be closer to the clinical efficacy threshold, potentially enhancing treatment outcomes and improving patient prognosis.
  • Patient Recruitment: GT Biopharma is actively screening patients for Cohort 4 and anticipates initiating dosing in the coming weeks, which will provide a more comprehensive clinical update in the first quarter of 2026.
  • Technology Platform: GTB-3650 employs the company's proprietary TriKE platform technology, aiming to target cancer cells by stimulating patients' natural killer cells, showcasing innovative potential in treating acute myeloid leukemia and high-risk myelodysplastic syndrome.
[object Object]
Preview
7.5
12-03NASDAQ.COM
Kura Receives $135 Million Milestone Payment Following First U.S. Commercial Sale of KOMZIFTI

  • Kura Oncology's Milestone Payment: Kura Oncology is set to receive a $135 million milestone payment from Kyowa Kirin following the first U.S. commercial sale of KOMZIFTI, which was recently approved for treating a specific type of acute myeloid leukemia.

  • Partnership Details: Kura and Kyowa Kirin entered a $1.5 billion global partnership to develop and commercialize KOMZIFTI, with profits split 50/50 in the U.S. and Kyowa Kirin holding exclusive rights outside the U.S.

  • Financial Overview: As of November 2025, Kura has received a total of $465 million from the partnership, including an upfront payment and milestone payments.

  • Market Performance: KURA shares closed at $11.13, reflecting a 2.71% decrease, but showed a slight increase in pre-market trading at $11.30.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Kura Oncology Inc (KURA) stock price today?

The current price of KURA is 11.98 USD — it has increased 0.08 % in the last trading day.

arrow icon

What is Kura Oncology Inc (KURA)'s business?

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include KOMZIFTI (Ziftomenib), Tipifarnib, and Darlifarnib (KO-2806). Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a selective investigational inhibitor of the menin-KMT2A protein-protein interaction for the treatment of genetically defined subsets of acute leukemias. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is an FTI, is being evaluated in a Phase I first-in-human trial as a monotherapy and in combination with other targeted therapies.

arrow icon

What is the price predicton of KURA Stock?

Wall Street analysts forecast KURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KURA is 26.88 USD with a low forecast of 11.00 USD and a high forecast of 40.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Kura Oncology Inc (KURA)'s revenue for the last quarter?

Kura Oncology Inc revenue for the last quarter amounts to 20.75M USD, decreased % YoY.

arrow icon

What is Kura Oncology Inc (KURA)'s earnings per share (EPS) for the last quarter?

Kura Oncology Inc. EPS for the last quarter amounts to -0.85 USD, increased 34.92 % YoY.

arrow icon

What changes have occurred in the market's expectations for Kura Oncology Inc (KURA)'s fundamentals?

The market is revising Downward the revenue expectations for Kura Oncology, Inc. (KURA) for FY2025, with the revenue forecasts being adjusted by -20.66% over the past three months. During the same period, the stock price has changed by 45.74%.
arrow icon

How many employees does Kura Oncology Inc (KURA). have?

Kura Oncology Inc (KURA) has 192 emplpoyees as of December 05 2025.

arrow icon

What is Kura Oncology Inc (KURA) market cap?

Today KURA has the market capitalization of 1.04B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free